Régulation de l'homéostasie du cholestérol par les récepteurs nucléaires PPARa et LXR dans les macrophages primaires humains

Les maladies cardiovasculaires représentent la cause majeure de mortalité dans les pays industrialisés. L'athérosclérose est à l'origine de nombreux décès par accidents ischémiques aigüs. Les macrophages jouent un rôle essentiel dans le développement de cette maladie. Les récepteurs nucléaires Peroxysome proliferators-activated receptor (PPAR) a et Liver X receptors (LXR) sont des récepteurs nucléaires exprimés dans les macrophages humains et impliqués dans la modulation du métabolisme des lipides. Des études cliniques chez l'homme et sur des modèles animaux ont montré que l'activation de PPARa et des LXR par leurs ligands synthétiques peut inhiber le développement de l'athérosclérose. Ceci, indépendamment de leur effet sur les lipides plasmatiques par leurs actions au niveau de la paroi artérielle. Dans un premier temps, nous avons montré dans les macrophages primaires humains que les agonistes des récepteurs nucléaires PPAR et LXR augmentent l'efflux de cholestérol vers l'apoAI non seulement par l'induction de l'expression du transporteur ABCA1 mais également en mobilisant le cholestérol vers la membrane plasmique par l'induction des protéines NPC-1 et NPC-2. Dans un second temps, nous avons mis en évidence que l'activation de LXR induit également la captation sélective des esters de cholestérol provenant des HDL. Cette régulation fonctionnelle est associée à une augmentation de l'efflux de cholestérol vers ces mêmes HDL et à une augmentation de l'expression de différentes protéines telles que l'apolipoprotéine E, la lipoprotéine lipase et la cavéoline impliquées dans les phénomènes de captation des esters de cholestérol. Ceci suggère que l'effet anti-athérogène de LXR soit assuré, en partie, par l'augmentation des flux du cholestérol dans le macrophage humain. Nos travaux sont donc en étroite adéquation avec l'hypothèse de propriétés anti athéroscléreuses des récepteurs nucléaires par leur action directe sur la régulation du métabolisme du cholestérol dans le macrophage.The cardiovascular diseases represent the major cause of mortality in industrial countries. Atherosclerosis is responsible of many ischemic troubles. Macrophages play a pivotal role in the development of atherosclerosis. Peroxysome proliferators-activated receptor (PPAR) alpha and Liver X receptors (LXR) are nuclear receptors expressed in human macrophages that regulate the expression of genes controlling lipid metabolism. Clinical trials and studies on animal models show that PPAR alpha and LXRs agonists can repress development of atherosclerosis by their actions on arterial wall, especially on cholesterol homeostasis regulation in macrophages. First, we have shown that PPAR and LXR agonists induce NPC-1 and NPC-2 genes and proteins expression and stimulate the postlysosomal mobilization of cholesterol to plasma membrane, associated with inhibition of cellular cholesterol esterification. Cholesterol becomes more available for its efflux to extracellular acceptors via the ABCA1 pathway. Then, we have shown that LXR agonists induce a strong increase in selective cholesteryl ester uptake. This functional regulation is associated with an induction of cholesterol efflux out of the cell and an induction in several protein expressions as apolipoprotein E, lipoprotein lipase ans caveolin. These proteins are associated to cholesteryl ester uptake phenomenae. These results suggest that the LXR athero-protective effect is mediated in part by enhanced fluxes in cholesterol intracellular trafficking in the human macrophage.LILLE2-BU Santé-Recherche (593502101) / SudocSudocFranceF

Intestine-Liver Cross-talk in Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

International audienceType 2 diabetes (T2D) and Non-Alcoholic Fatty Liver Disease (NAFLD) are pathologies whose prevalence continues to increase worldwide. Both diseases are precipitated by an excessive caloric intake, which promotes insulin resistance and fatty liver. The role of the intestine and its crosstalk with the liver in the development of these metabolic diseases is receiving increasing attention. Alterations in diet-intestinal microbiota interactions lead to the dysregulation of intestinal functions, resulting in altered metabolite and energy substrate production and increased intestinal permeability. Connected through the portal circulation, these changes in intestinal functions impact the liver and other metabolic organs, such as visceral adipose tissue, hence participating in the development of insulin resistance, and worsening T2D and NAFLD. Thus, targeting the intestine may be an efficient therapeutic approach to cure T2D and NAFLD. In this review, we will first introduce the signaling pathways linking T2D and NAFLD. Next, we will address the role of the gut-liver crosstalk in the development of T2D and NAFLD, with a particular focus on the gut microbiota and the molecular pathways behind the increased intestinal permeability and inflammation. Finally, we will summarize the therapeutic strategies which target the gut and its functions and are currently used or under development to treat T2D and NAFLD

NEW FINDINGS IN THE REGULATION OF INTESTINAL GLUCOSE ABSORPTION BY DIETARY PROTEINS

International audienc

NEW FINDINGS IN THE REGULATION OF INTESTINAL GLUCOSE ABSORPTION BY DIETARY PROTEINS

International audienc

Reconstitution des protéines d'enveloppe du virus de l'hépatite C en liposomes :un outil pour étudier l'attachement viral.

info:eu-repo/semantics/nonPublishe

Activation of intestinal peroxisome proliferator-activated receptor-α increases high-density lipoprotein production.

International audienceAIMS: Peroxisome proliferator-activated receptor (PPAR)-α is a transcription factor controlling lipid metabolism in liver, heart, muscle, and macrophages. Peroxisome proliferator-activated receptor-α activation increases plasma HDL cholesterol and exerts hypotriglyceridaemic actions via the liver. However, the intestine expresses PPAR-α, produces HDL and chylomicrons, and is exposed to diet-derived PPAR-α ligands. Therefore, we examined the effects of PPAR-α activation on intestinal lipid and lipoprotein metabolism. METHODS AND RESULTS: The impact of PPAR-α activation was evaluated in term of HDL-related gene expression in mice, ex vivo in human jejunal biopsies and in Caco-2/TC7 cells. Apolipoprotein-AI/HDL secretion, cholesterol esterification, and trafficking were also studied in vitro. In parallel to improving plasma lipid profiles and increasing liver and intestinal expression of fatty acid oxidation genes, treatment with the dual PPAR-α/δ ligand GFT505 resulted in a more pronounced increase in plasma HDL compared with fenofibrate in mice. GFT505, but not fenofibrate, increased the expression of HDL production genes such as apolipoprotein-AI and ATP-binding cassette A1 transporter in murine intestines. A similar increase was observed upon PPAR-α activation of human biopsies and Caco-2/TC7 cells. Additionally, HDL secretion by Caco-2/TC7 cells increased. Moreover, PPAR-α activation decreased the cholesterol esterification capacity of Caco-2/TC7 cells, modified cholesterol trafficking, and reduced apolipoprotein-B secretion. CONCLUSION: Peroxisome proliferator-activated receptor-α activation reduces cholesterol esterification, suppresses chylomicron, and increases HDL secretion by enterocytes. These results identify the intestine as a target organ of PPAR-α ligands with entero-hepatic tropism to reduce atherogenic dyslipidaemia

Role of dietary proteins in the regulation of intestinal glucose absorption

International audienc